Urocortins

Neuropeptides of about 40 amino acids which are structurally similar to CORTICOTROPIN-RELEASING FACTOR. Unlike CRF acting primarily through type 1 CRF RECEPTORS, urocortins signal preferentially through type 2 CRF receptors. Urocortins have wide tissue distribution from fish to mammals, and diverse functions. In mammals, urocortins can suppress food intake, delays gastric emptying, and decreases heat-induced edema.

Also Known As:

Networked: 268 relevant articles (21 outcomes, 51 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rademaker, Miriam T: 22 articles (10/2015 - 10/2002)
2.	Richards, A Mark: 20 articles (03/2015 - 10/2002)
3.	Li, Shengnan: 16 articles (11/2015 - 06/2005)
4.	Charles, Christopher J: 13 articles (10/2015 - 10/2002)
5.	Petraglia, Felice: 13 articles (03/2012 - 08/2002)
6.	Stephanou, Anastasis: 10 articles (11/2014 - 03/2002)
7.	Scarabelli, Tiziano M: 10 articles (11/2014 - 07/2002)
8.	Jin, Lai: 9 articles (11/2015 - 08/2009)
9.	Takahashi, Kazuhiro: 8 articles (04/2014 - 01/2002)
10.	Florio, Pasquale: 8 articles (09/2011 - 08/2002)

Related Diseases

1.	Ischemia 09/17/2002 - "Urocortin is a novel cardioprotective agent that can protect cardiac myocytes from the damaging effects of ischemia/reperfusion both in culture and in the intact heart and is effective when given at reperfusion. " 06/01/2005 - "Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts." 01/01/2004 - "These results suggest that ischemia-reperfusion impairs the coronary vasodilation to urocortin and produces endothelial dysfunction and that this endothelial dysfunction may be improved by urocortin." 03/19/2008 - "This study evaluates whether cardiac ischemia induces release of urocortin, before and independently from myocyte cell death. " 01/01/2004 - "To study whether urocortin also protects coronary endothelial function during ischemia-reperfusion, hearts from Sprague-Dawley rats were perfused at constant flow and then exposed to 15 mins ischemia followed by 15 mins reperfusion. "
2.	Reperfusion Injury 06/01/2005 - "In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms." 12/01/2014 - "Recent studies have shown that urocortins exert various biological effects in the cardiovascular system, such as vasodilation, positive inotropic and lusitropic effects, as well as cardioprotection against ischemia-reperfusion injury. " 01/01/2012 - "Recent studies have shown that urocortins have various biological actions in the cardiovascular system, such as a vasodilator action, a positive inotropic action, a cardioprotective action against ischemia/reperfusion injury, and suppressive actions against the renin angiotensin system and the sympathetic nervous system. " 06/01/2005 - "The aim of this study was to investigate the effects of urocortin (UCN) on oxidative stress and the mechanisms of urocortin on ischemia-reperfusion injury in vivo in the rat model. " 11/01/2009 - "We previously reported that iatrogenic ischemia/reperfusion injury caused myocyte induction of urocortin, an endogenous cardioprotective peptide. "
3.	Heart Failure 01/01/2011 - "Urocortin 2 is beneficial in heart failure, but the underlying cellular mechanisms are not completely understood. " 10/01/2013 - "Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy)." 06/01/2011 - "In the current study, we administered a 4-day infusion of a vehicle control (0.9% saline; n=6) or urocortin 2 (0.75 μg/kg per hour; n=6) to sheep with pacing-induced heart failure. " 08/01/2010 - "Indeed, a number of studies have demonstrated increased urocortin activity in experimental and clinical heart failure, with apparent augmented responses in these states. " 04/01/2007 - "Safety trials for intravenous urocortin treatment have already begun for the treatment of congestive heart failure. "
4.	Anoxia (Hypoxia) 10/01/2003 - "Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes." 08/01/2004 - "The aim of this study was to determine the effect of in vitro hypoxia on human trophoblastic urocortin production. " 11/15/2009 - "The human urocortin 2 gene is regulated by hypoxia: identification of a hypoxia-responsive element in the 3'-flanking region." 08/01/2004 - "The effect of hypoxia on placental urocortin production is not known. " 08/01/2004 - "Effect of hypoxia on urocortin production in human gestational trophoblasts in vitro."
5.	Myocardial Infarction 03/01/2015 - "Chronic urocortin 2 administration improves cardiac function and ameliorates cardiac remodeling after experimental myocardial infarction." 03/01/2015 - "The impact of chronic urocortin 2 (Ucn2) treatment after myocardial infarction (MI) has not previously been investigated. " 10/01/2010 - "Despite its proposed cardioprotective effect, the role of plasma urocortin in acute myocardial infarction (AMI) remains unknown. " 10/01/2010 - "Plasma urocortin in acute myocardial infarction patients." 07/21/2008 - "This growing evidence suggests that urocortins may have a prognostic value as well as being a potential therapeutic treatment for heart failure and myocardial infarction patients. "

Related Drugs and Biologics

1.	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)
2.	Corticotropin-Releasing Hormone
3.	Peptides
4.	Neuropeptides
5.	Adrenomedullin
6.	Acetylcholine (Acetylcholine Chloride)
7.	Caspase 3 (Caspase-3)
8.	HMGB1 Protein (HMG1)
9.	Atrial Natriuretic Factor (ANF)
10.	Bradykinin

Related Therapies and Procedures

1.	Injections
2.	Ligation
3.	Intravenous Infusions
4.	Intraperitoneal Injections
5.	Analgesia